These quotes from 1q earnings call - will update shortly with content from recent 2q CC!
Earnings call transcript excerpts c/o SeekingAlpha.
Turning to ENTEREG, we're starting to see the positive results of our learning last year. The first quarter this year looks particularly strong, up close to 19% in net revenue against Q1 last year. Remember that in Q1 of last year, we were just starting the relaunch of ENTEREG and had not begun to rollout the effort to all hospitals. For the full year for ENTEREG, we are on target against the 2013 net revenue guidance we provided, a range of between $45 million and $50 million.
Finally, we continue to generate service revenues for our support of DIFICID in U.S. hospitals, as co-promote partner for Optima. This relationship is set to end in late July, when our 2-year agreement expires.
Earnings call transcript excerpts c/o SeekingAlpha.
Turning to ENTEREG, we're starting to see the positive results of our learning last year. The first quarter this year looks particularly strong, up close to 19% in net revenue against Q1 last year. Remember that in Q1 of last year, we were just starting the relaunch of ENTEREG and had not begun to rollout the effort to all hospitals. For the full year for ENTEREG, we are on target against the 2013 net revenue guidance we provided, a range of between $45 million and $50 million.
Finally, we continue to generate service revenues for our support of DIFICID in U.S. hospitals, as co-promote partner for Optima. This relationship is set to end in late July, when our 2-year agreement expires.
RSS Feed
